AAP
AKBA icon

Arax Advisory Partners’s Akebia Therapeutics AKBA Stock Holding History

Arax Advisory Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Buy
54,999
+15,897
+41% +$18.9K ﹤0.01% 3089
2026
Q1 		$54.4K Buy
39,102
+9
+0% +$12 ﹤0.01% 1661
2025
Q4 		$62.9K Sell
39,093
-507
-1% -$1.06K ﹤0.01% 1504
2025
Q3 		$108K Buy
39,600
+14,783
+60% +$49.2K ﹤0.01% 1507
2025
Q2 		$90.3K Hold
24,817
– – ﹤0.01% 977
2025
Q1 		$47.6K Buy
24,817
+11,117
+81% +$22.7K ﹤0.01% 961
2024
Q4 		$26K Buy
+13,700
New +$23.8K ﹤0.01% 1110

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arax Advisory Partners's AKBA Position: Q2 2026 in Review

Arax Advisory Partners increased its Akebia Therapeutics (AKBA) stake by 41% in Q2 2026, buying an estimated $18.9K and bringing the position to 54,999 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3089.

Arax Advisory Partners first reported a position in AKBA in Q4 2024 and has held it in 7 quarters since. The position peaked at $108K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Arax Advisory Partners held 54,999 shares of Akebia Therapeutics worth $62.7K as of Q2 2026.
  • Arax Advisory Partners bought 15,897 Akebia Therapeutics shares in Q2 2026, an estimated $18.9K.
  • Akebia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3089 holding.
  • Arax Advisory Partners first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Akebia Therapeutics position peaked at $108K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.